NASDAQ · PTN
Palatin Technologies, Inc.
$4.93-$0.17 (-3.33%)
Palatin Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.1% below the high.
Loading market information…
NASDAQ · MTP · USD
Stock price, earnings
Quote as of Mar 24, 2023, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Midatech Pharma plc’s quoted price sits in the lower half of its reported 52-week range, 98.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Midatech Pharma plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Midatech Pharma plc is a pharmaceutical company focused on the research and development of drug delivery technologies and therapeutic solutions across the United Kingdom, Europe, and international markets. Its active pipeline includes MTX110, an investigational direct-delivery treatment for aggressive brain tumors such as diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. Also in development are MTX114, a topical immunosuppressant for managing psoriasis; MTD211, an extended-release formulation of brexpiprazole for schizophrenia and as an adjunct for major depressive disorder; and MTD219, a long-acting version of tacrolimus designed to mitigate the risk of organ transplant rejection. The company also leverages proprietary drug delivery platforms: Q-Sphera, a polymer microsphere microtechnology for sustained drug release; MidaSolve, an oligosaccharide nanotechnology enabling the solubilization and direct, localized liquid administration of drugs into tumors; and MidaCore, a gold nanoparticle system engineered for targeted delivery of chemotherapeutic or immunotherapeutic agents to disease sites. Founded in 2000, Midatech Pharma plc is headquartered in Cardiff, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:00 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.93-$0.17 (-3.33%)
Palatin Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.1% below the high.
$0.09-$0.03 (-24.84%)
Novan, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.17% below the high.
$0.25-$0.09 (-27.68%)
Notable Labs, Ltd.’s quoted price sits in the lower half of its reported 52-week range, 94.15% below the high.
$0.85-$0.26 (-23.42%)
Fresh2 Group Limited’s quoted price sits in the lower half of its reported 52-week range, 90.56% below the high.
$0.17-$0.04 (-18.69%)
Sientra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$0.10$0.00 (0.0%)
Cutera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.77% below the high.
$0.07-$0.07 (-50.87%)
VBI Vaccines Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.16% below the high.
$0.24-$0.00 (-0.82%)
PolarityTE, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.32% below the high.
